<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166760</url>
  </required_header>
  <id_info>
    <org_study_id>TAKE4</org_study_id>
    <nct_id>NCT04166760</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of Whey Compounds in Patients With Diabetes Mellitus Type 2.</brief_title>
  <official_title>Metabolic Effects of Whey Compounds in Patients With Diabetes Mellitus Type 2.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of our study is to investigate the metabolic effects of a i) ordinary whey
      protein (WHE) and ii) a specific whey protein fraction (speWHE) when the interventions are
      ingested by patients with type 2 diabetes 30 minutes prior to an oral glucose tolerance test
      (OGTT). We will also investigate the glucose response when the patients ingest the
      interventions at home in their own environment 30 minutes before breakfast and dinner (2days)
      and also monitor glucose levels without interventions (2 days).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double blinded, randomized, crossover design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in iAUC for insulin between WHE and speWHE</measure>
    <time_frame>OGTT, 3 hours.</time_frame>
    <description>Difference in iAUC for insulin between WHE and speWHE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in iAUC and concentration differences for GIP</measure>
    <time_frame>OGTT 3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in iAUC and concentration differences for GLP-1</measure>
    <time_frame>OGTT 3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in iAUC and concentration differences for glucagon</measure>
    <time_frame>OGTT 3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in iAUC and concentration differences for glucose</measure>
    <time_frame>OGTT 3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in iAUC and concentration differences for C-peptid</measure>
    <time_frame>OGTT 3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in iAUC and concentration differences for FFA</measure>
    <time_frame>OGTT 3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity measurements</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>continuous glucose measurement (CGM)</measure>
    <time_frame>5 days</time_frame>
    <description>CGM with time in normal range 4-10 mmol/l, peak after a meal, AUC in the days with the interventions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>WHE (regular whey protein)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular whey protein. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>speWHE (specific whey protein compound)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specific whey protein compound. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>speWHE</intervention_name>
    <description>25 gram of a specific whey fraction (confidential)</description>
    <arm_group_label>speWHE (specific whey protein compound)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>WHE</intervention_name>
    <description>25 gram protein of a regular whey compound</description>
    <arm_group_label>WHE (regular whey protein)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Type 2 diabetes (T2D) diagnosis

          -  No medical treatment or metformin/sulfonylureas(SU) alone in the treatment of T2D

          -  No daily use of protein drinks

          -  Hba1c between 40 mmol/mol and 69 mmol/mol

          -  20 kg/m2 &lt; BMI &lt; 35 kg/m2

          -  Screening blood test: 1200 pmol/l &gt; C-peptid &gt; 370 pmol/l

        Exclusion Criteria:

          -  Other diabetes medication than metformin/SU (e.g. insulin, GLP-1 analog, DPP-4
             inhibitor, SGLT2-inhibitor)

          -  Affected screening blood test assessed by the primary investigator(PI)/sponsor

          -  Does not understand or speak danish

          -  Milk allergy

          -  PI finds the patient not fit (e.g. mental illness, too nervous or other)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels Jessen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Medicinsk forskningslaboratorium for Diabetes og Hormonsygdomme og Steno Diabetes Center Aarhus (M-lab), Aarhus universitetshospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicinsk forskningslaboratorium for Diabetes og Hormonsygdomme og Steno Diabetes Center Aarhus (M-lab), Aarhus universitetshospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

